PlainRecalls
FDA Drug Moderate Class II Terminated

Rifampin Capsules USP, 300 mg, 30-count bottle; Rx Only, Manufactured for: Lupin Pharmaceuticals Baltimore, Maryland 21202, Manufactured by: Lupin Limited Aurangabad 431 210 India. NDC 68180-659-06

Reported: January 18, 2023 Initiated: December 12, 2022 #D-0100-2023

Product Description

Rifampin Capsules USP, 300 mg, 30-count bottle; Rx Only, Manufactured for: Lupin Pharmaceuticals Baltimore, Maryland 21202, Manufactured by: Lupin Limited Aurangabad 431 210 India. NDC 68180-659-06

Reason for Recall

Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term stability study.

Details

Units Affected
16,056 30 count bottles
Distribution
Distributed Nationwide in the USA
Location
Baltimore, MD

Frequently Asked Questions

What product was recalled?
Rifampin Capsules USP, 300 mg, 30-count bottle; Rx Only, Manufactured for: Lupin Pharmaceuticals Baltimore, Maryland 21202, Manufactured by: Lupin Limited Aurangabad 431 210 India. NDC 68180-659-06. Recalled by Lupin Pharmaceuticals Inc.. Units affected: 16,056 30 count bottles.
Why was this product recalled?
Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term stability study.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 18, 2023. Severity: Moderate. Recall number: D-0100-2023.